133 related articles for article (PubMed ID: 36330625)
1. The Treatment of Parkinson's Disease with Sodium Oxybate.
Mamelak M
Curr Mol Pharmacol; 2023; 16(5):564-579. PubMed ID: 36330625
[TBL] [Abstract][Full Text] [Related]
2. Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.
Dragicevic E; Poetschke C; Duda J; Schlaudraff F; Lammel S; Schiemann J; Fauler M; Hetzel A; Watanabe M; Lujan R; Malenka RC; Striessnig J; Liss B
Brain; 2014 Aug; 137(Pt 8):2287-302. PubMed ID: 24934288
[TBL] [Abstract][Full Text] [Related]
3. Generation of a Novel Mouse Model of Parkinson's Disease via Targeted Knockdown of Glutamate Transporter GLT-1 in the Substantia Nigra.
Zhang Y; Meng X; Jiao Z; Liu Y; Zhang X; Qu S
ACS Chem Neurosci; 2020 Feb; 11(3):406-417. PubMed ID: 31909584
[TBL] [Abstract][Full Text] [Related]
4. Pathological histone acetylation in Parkinson's disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibition.
Harrison IF; Smith AD; Dexter DT
Neurosci Lett; 2018 Feb; 666():48-57. PubMed ID: 29273397
[TBL] [Abstract][Full Text] [Related]
5. Parkinson's Disease, the Dopaminergic Neuron and Gammahydroxybutyrate.
Mamelak M
Neurol Ther; 2018 Jun; 7(1):5-11. PubMed ID: 29368093
[TBL] [Abstract][Full Text] [Related]
6. RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson's Disease.
Ahlers-Dannen KE; Spicer MM; Fisher RA
Mol Pharmacol; 2020 Dec; 98(6):730-738. PubMed ID: 32015009
[TBL] [Abstract][Full Text] [Related]
7. Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease.
Duda J; Pötschke C; Liss B
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):156-178. PubMed ID: 26865375
[TBL] [Abstract][Full Text] [Related]
8. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
[TBL] [Abstract][Full Text] [Related]
9. IDH2 deficiency promotes mitochondrial dysfunction and dopaminergic neurotoxicity: implications for Parkinson's disease.
Kim H; Kim SH; Cha H; Kim SR; Lee JH; Park JW
Free Radic Res; 2016 Aug; 50(8):853-60. PubMed ID: 27142242
[TBL] [Abstract][Full Text] [Related]
10. Myrcene Salvages Rotenone-Induced Loss of Dopaminergic Neurons by Inhibiting Oxidative Stress, Inflammation, Apoptosis, and Autophagy.
Azimullah S; Jayaraj RL; Meeran MFN; Jalal FY; Adem A; Ojha S; Beiram R
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677744
[TBL] [Abstract][Full Text] [Related]
11. Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice.
Luo Z; Ahlers-Dannen KE; Spicer MM; Yang J; Alberico S; Stevens HE; Narayanan NS; Fisher RA
JCI Insight; 2019 May; 5(13):. PubMed ID: 31120439
[TBL] [Abstract][Full Text] [Related]
12. Trib3 Is Elevated in Parkinson's Disease and Mediates Death in Parkinson's Disease Models.
Aimé P; Sun X; Zareen N; Rao A; Berman Z; Volpicelli-Daley L; Bernd P; Crary JF; Levy OA; Greene LA
J Neurosci; 2015 Jul; 35(30):10731-49. PubMed ID: 26224857
[TBL] [Abstract][Full Text] [Related]
13. Activated microglia facilitate the transmission of α-synuclein in Parkinson's disease.
Zheng T; Zhang Z
Neurochem Int; 2021 Sep; 148():105094. PubMed ID: 34097990
[TBL] [Abstract][Full Text] [Related]
14. Dopamine-dependent early synaptic and motor dysfunctions induced by α-synuclein in the nigrostriatal circuit.
Tozzi A; Sciaccaluga M; Loffredo V; Megaro A; Ledonne A; Cardinale A; Federici M; Bellingacci L; Paciotti S; Ferrari E; La Rocca A; Martini A; Mercuri NB; Gardoni F; Picconi B; Ghiglieri V; De Leonibus E; Calabresi P
Brain; 2021 Dec; 144(11):3477-3491. PubMed ID: 34297092
[TBL] [Abstract][Full Text] [Related]
15. Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation.
Liu G; Yu J; Ding J; Xie C; Sun L; Rudenko I; Zheng W; Sastry N; Luo J; Rudow G; Troncoso JC; Cai H
J Clin Invest; 2014 Jul; 124(7):3032-46. PubMed ID: 24865427
[TBL] [Abstract][Full Text] [Related]
16. Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease.
Alarcón-Arís D; Recasens A; Galofré M; Carballo-Carbajal I; Zacchi N; Ruiz-Bronchal E; Pavia-Collado R; Chica R; Ferrés-Coy A; Santos M; Revilla R; Montefeltro A; Fariñas I; Artigas F; Vila M; Bortolozzi A
Mol Ther; 2018 Feb; 26(2):550-567. PubMed ID: 29273501
[TBL] [Abstract][Full Text] [Related]
17. Reduced Nicotinamide Adenine Dinucleotide Phosphate Inhibits MPTP-Induced Neuroinflammation and Neurotoxicity.
Zhou Y; Wu J; Sheng R; Li M; Wang Y; Han R; Han F; Chen Z; Qin ZH
Neuroscience; 2018 Nov; 391():140-153. PubMed ID: 30195055
[TBL] [Abstract][Full Text] [Related]
18. LRRK2-G2019S mice display alterations in glutamatergic synaptic transmission in midbrain dopamine neurons.
Skiteva O; Yao N; Sitzia G; Chergui K
J Neurochem; 2022 Apr; 161(2):158-172. PubMed ID: 35152441
[TBL] [Abstract][Full Text] [Related]
19. NADPH ameliorates MPTP-induced dopaminergic neurodegeneration through inhibiting p38MAPK activation.
Zhou JS; Zhu Z; Wu F; Zhou Y; Sheng R; Wu JC; Qin ZH
Acta Pharmacol Sin; 2019 Feb; 40(2):180-191. PubMed ID: 29769744
[TBL] [Abstract][Full Text] [Related]
20. Apocyanin, a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinson's Disease Model.
Sharma N; Nehru B
Mol Neurobiol; 2016 Jul; 53(5):3326-3337. PubMed ID: 26081143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
